article imageOverview: The Gibco LV-MAX Lentiviral Production System is the first optimized system that provides a scalable and high-yield lentiviral vector (LVV) production platform. It is based on a high-density suspension,culture of HEK 293-derived Viral Production Cells in chemically defined, serum-free and protein-free LV-MAX Production Medium. Optimal viral titer yield is mediated by our advanced lipid nanoparticle-based transfection reagent in combination with a novel lentiviral-specific enhancer and supplement. All components work synergistically to generate superior and functional lentiviral particles under serum-free conditions compared to conventional polyethylenimine (PEI), serum-based culture systems.

Key Applications: Cell and gene therapy research

Features/Benefits: 

  • High titers—greater than 1 x 108 TU/mL (unconcentrated LVV-GFP)
  • Scalable suspension system—lentiviral production from a 96 deep-well plate to a 2 L bioreactor
  • Serum-free—eliminating animal-origin components and associated risks
  • Cost-effective—over 50% cost reduction compared to PEI-based lentiviral production methods

www.thermoscientific.com/lentiviral 

Gibco LV-MAX Lentiviral Production System is for Research Use Only. Not for use in diagnostic procedures.

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of $18 billion and more than 55,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, and increase laboratory productivity. Through our premier brands—Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services—we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. Visit www.thermofisher.com